Skip to main content
logo
Duality Biotherapeutics, Inc. (HKG:9606)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
172.20
-11.70 (-6.36%)
Sep 10, 2026, 1:14 PM HKT

Duality Biotherapeutics Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23
Revenue
842.131,8521,9411,787
Revenue Growth
-61.20%-4.61%8.66%-
Cost of Revenue
1,0761,2631,157427.66
Gross Profit
-233.67589.09784.671,359
Selling, General & Admin
170.61214.61158.6962.57
Research & Development
1,095837.77815.38559
Other Operating Expenses
-6.75-3.16-2.361.06
Operating Expenses
1,2591,049971.71622.62
Operating Income
-1,493-460.12-187.04736.27
Interest Expense
-3.18-1.21-0.25-0.19
Interest & Investment Income
111.7499.3148.1134.48
Currency Exchange Gain (Loss)
-76.21-34.7412.2741.94
Other Non Operating Income (Expenses)
13.73-2,206-873.42-1,018
EBT Excluding Unusual Items
-1,446-2,603-1,000-205.4
Asset Writedown
---21.35-
Other Unusual Items
7.997.997.123.15
Pretax Income
-1,439-2,595-1,015-202.25
Income Tax Expense
--35.89155.26
Net Income
-1,439-2,595-1,050-357.51
Net Income to Common
-1,439-2,595-1,050-357.51
Net Income Growth
----
Shares Outstanding (Basic)
896588
Shares Outstanding (Diluted)
896588
Shares Change
259.84%714.45%--
EPS (Basic)
-16.09-39.82-131.30-44.69
EPS (Diluted)
-16.09-39.82-131.30-44.69
EPS Growth
----

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23
Free Cash Flow
-830.38183.08281.7805.05
Free Cash Flow Per Share
-9.292.8135.21100.63
Gross Margin
-27.75%31.81%40.42%76.06%
Operating Margin
-177.24%-24.85%-9.63%41.21%
Profit Margin
-170.82%-140.13%-54.11%-20.01%
Free Cash Flow Margin
-98.61%9.89%14.51%45.06%
EBITDA
-1,484-452.7-182.46737.75
EBITDA Margin
-176.17%-24.45%-9.40%41.30%
D&A For EBITDA
8.967.434.581.48
EBIT
-1,493-460.12-187.04736.27
EBIT Margin
-177.24%-24.85%-9.63%41.21%